title: The role of rituximab in adults with warm antibody autoimmune hemolytic anemia.
abstract: Warm antibody hemolytic anemia is the most common form of autoimmune hemolytic anemia. When therapy is needed, corticosteroids remain the cornerstone of initial treatment but are able to cure only a minority of patients (<20%). Splenectomy is usually proposed when a second-line therapy is needed. This classical approach is now challenged by the use of rituximab both as second-line and as first-line therapy. Second-line treatment with rituximab leads to response rates similar to splenectomy (∼70%), but rituximab-induced responses seem less sustained. However, additional courses of rituximab are most often followed by responses, at the price of reasonable toxicity. In some major European centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in adults, although no prospective study convincingly supports this attitude. A recent randomized study strongly suggests that in first-line treatment, rituximab combined with steroids is superior to monotherapy with steroids. If this finding is confirmed, rituximab will emerge as a major component of the management of warm antibody hemolytic anemia not only after relapse but as soon as treatment is needed.
authors.affiliation: Department of Hematology, University Hospitals Leuven, Leuven, Belgium; and.
authors.forename: Daan
authors.initials: D
authors.lastname: Dierickx
authors.affiliation: Department of Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
authors.forename: Alain
authors.initials: A
authors.lastname: Kentos
authors.affiliation: Department of Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
authors.forename: André
authors.initials: A
authors.lastname: Delannoy
mesh_terms: D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab